肝癌患者血清microRNA-21水平变化*

doi:10.3969/j.issn.1672-5069.2014.01.020

实用肝脏病杂志 ›› 2014, Vol. 17 ›› Issue (1): 68-70.doi: 10.3969/j.issn.1672-5069.2014.01.020

肝癌患者血清microRNA-21水平变化^*

郝清亚, 王以浪, 姚登福, 缪亚军, 印滇

226001 江苏省南通市第一人民医院肝胆外科（郝清亚）; 肿瘤科（王以浪,缪亚军,印滇）; 南通大学附属医院临床医学研究中心（姚登福）

收稿日期:2013-07-11 出版日期:2014-02-28 发布日期:2016-04-11
通讯作者: 王以浪,E-mail：oncowang@163.com
作者简介:郝清亚,男,31岁,医学硕士,住院医师。主要从事肝癌的分子诊断学研究。E-mail：895325173@qq.com
基金资助:
国家国际科技合作专项（2013DFA32150）; 南通市科技计划项目（S11904/ K2010026）

Serum level of microRNA-21 in patients with hepatocellular carcinoma

Hao Qingya, Wang Yilang, Yao Dengfu

First People’s Hospital,Natong 226001,Jiangsu Province,China

Received:2013-07-11 Online:2014-02-28 Published:2016-04-11

摘要/Abstract

摘要： 目的分析不同肝病患者血清microRNA-21 （miR-21）水平,以探讨miR-21对肝细胞癌（HCC）的诊断价值。方法以实时定量逆转录PCR法检测正常人、慢性乙型肝炎（CHB）、肝硬化和HCC患者（各组均为25例）血清miR-21水平,分析miR-21水平与HCC临床病理学特征的关系。结果正常人、CHB和肝硬化患者血清miR-21相对水平分别为（1.1±1.7）、（2.3±2.6）和（2.8±2.5）,而HCC患者为（22.6±4.4）,显著高于前三组（P<0.001）;HCC患者术后1w和1m血清miR-21相对水平分别为（18.4±3.5）和（3.1±2.7）,均较术前显著降低（P<0.001）;HCC患者血清miR-21水平与肿瘤大小、癌栓以及HBV感染相关,与肿瘤分化程度、数目和血清AFP水平无相关性。结论miR-21在HCC患者血清中显著升高,可能作为HCC早期诊断的潜在标志。

关键词: 肝细胞癌, miRNA-21, 血清, 诊断

Abstract: Objective To evaluate serum level of microRNA-21（miR-21） in normal persons and patients with different liver diseases,and to investigate its effect in the diagnosis of hepatocellular carcinoma（HCC）. Methods The serum level of miR-21 in healthy controls （n=25）,patients with chronic hepatitis B（CHB,n=25）, cirrhosis（n=25）,and HCC（n=25） were measured by real-time quantitative RT-PCR. The relationships between serum miR-21 levels and clinical pathological features of HCC were also investigated. Results The relative serum levels of miR-21 in normal controls,CHB and cirrhotic patients were（1.1±1.7）,（2.3±2.6） and （2.8±2.5）,respectively,all of which were significantly lower than that in HCC patients（22.6±4.4）,P<0.001;The relative serum levels of miR-21 in HCC patients one week and one month after surgery were（18.4±3.5） and （3.1±2.7）,respectively,significantly lower than that before operation（22.6±4.4）,P<0.001;Serum levels of miR-21 were correlated with tumor size,tumor thrombosis and HBV infection,but not with tumor numbers,tumor differentiation and serum AFP levels. Conclusions Serum levels of miR-21 is elevated in HCC patients and might be used as a potential biomarker for the early diagnosis of HCC.

Key words: Hepatocellular carcinoma, MicroRNA-21, Serum, Diagnosis

郝清亚, 王以浪, 姚登福, 缪亚军, 印滇. 肝癌患者血清microRNA-21水平变化^*[J]. 实用肝脏病杂志, 2014, 17(1): 68-70.

Hao Qingya, Wang Yilang, Yao Dengfu. Serum level of microRNA-21 in patients with hepatocellular carcinoma[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(1): 68-70.

参考文献

[1] Baig JA,Alam JM,Mahmood SR,et al. Hepatocellular carcinoma（HCC） and diagnostic significance of alpha-fetoprotein （AFP）. J Ayub Med Coll Abbottabad,2009,21（1）：72-75.
[2] Marquardt JU,Galle PR,Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma（HCC）：an emerging field for advanced technologies. J Hepatol,2012,56（1）：267-275.
[3] Braconi C,Henry JC,Kogure T,et al. The role of microRNAs in human liver cancers.Semin Oncol,2011,38（6）：752-763.
[4] Law PT,Wong N. Emerging roles of microRNA in the intracellular signaling networks of hepatocellular carcinoma. J Gastroenterol Hepatol,2011,26（3）：437-449.
[5] Zhu Q,Wang Z,Hu Y,et al. miR-21 promotes migration and invasion by the miR-21 -PDCD4-AP-1 feedback loop in human hepatocellular carcinoma. Oncol Rep,2012,27（5）：1660-1668.
[6] 中华医学会肝病学分会和感染病学会. 慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-90.
[7] 中国抗癌协会肝癌专业委员会、中国抗癌协会临床肿瘤学协作专业委员会和中华医学会肝病学分会. 原发性肝癌规范化诊治的专家共识. 实用肝脏病杂志,2009,12（5）：321-328.
[8] Livak KJ,Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2（-Delta Delta C（T）. Methods,2001,25（4）：402-408.
[9] Wang L,Tang H,Thayanithy V,et al. Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res,2009,69（24）：9490-9497.
[10] Gabriely G,Wurdinger T,Kesari S,et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol,2008,28（17）：5369-5380.
[11] Schetter AJ,Leung SY,Sohn JJ,et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA,2008,299（4）：425-436.
[12] Vinciguerra M,Sgroi A,Veyrat-Durebex C,et al. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog（PTEN）via microRNA-21 upregulation in hepatocytes. Hepatology,2009,49（4）：1176-1184.
[13] Zhou R,Hu G,Gong AY,et al. Binding of NFkappaB p65 subunit to the promoter elements is involved in LPS-induced transactivation of miRNA genes in human biliary epithelial cells. Nucleic Acids Res,2010,38（10）：3222-3232.
[14] 王以浪,姚登福,吴玮,等. 小干扰RNA抑制核因子-κB活化对HepG2细胞凋亡的影响. 中华肝脏病杂志,2010,18（8）：609-613.
[15] Knoll S,Fürst K,Thomas S,et al. Dissection of cell context-dependent interactions between HBx and p53 family members in regulation of apoptosis：a role for HBV-induced HCC. Cell Cycle,2011,10（20）：3554-3565.
[16] Kew MC. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol,2011,26（1）：144-152.

肝癌患者血清microRNA-21水平变化^*

Serum level of microRNA-21 in patients with hepatocellular carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[2]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[3]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[4]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[5]	曾艳妮, 张灿, 毕俊英, 刘良进, 孟俊, 秦涛. MRI长时间延迟增强扫描诊断肝脏孤立性坏死性结节价值研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 900-903.
[6]	邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.
[7]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.
[8]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[9]	黄汉军, 鲁凤荣, 张灿. 基于Exchange血流动力学模型的MRI扫描参数诊断肝硬化临床价值分析*[J]. 实用肝脏病杂志, 2019, 22(5): 696-699.
[10]	朱俊, 丁莹, 王世清, 张野, 刘野, 刘泽刚. 围手术期应用乌司他丁治疗对肝细胞癌患者肝切除术后外周血Th22细胞百分比和血浆白细胞介素-22的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 720-723.
[11]	王刚, 赵洪波, 朱亚玲, 蒋保三, 张越美, 刁勇. 基于数据库分析肝细胞癌细胞XPO5基因水平变化及其临床意义*[J]. 实用肝脏病杂志, 2019, 22(5): 724-727.
[12]	洪佳, 吴晓宁, 尤红. 胆汁淤积性肝病的规范化诊断[J]. 实用肝脏病杂志, 2019, 22(5): 758-760.
[13]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[14]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[15]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.